$404.85▾ 0.73%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.38cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
58th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+5.8%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Highdebt to assets
Weak
High leverage relative to its assets.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Amgen Inc. turns 138¢ of every reported profit-dollar into real cash. Revenue is growing at a steady pace. Its valuation is around the middle of its own recent range. High leverage relative to its assets.
Key numbers
Valuation
EPS (TTM)$14.38
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin21.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$37.22B
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days18 articles
8 bullish9 neutral1 bearish
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class Action Investigation into Exposure of Patient Health Information
If I Were in My 20s, I'd Buy This Magnificent ETF and Hold It Until Retirement
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.